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Abstract
Introduction: Mutations affecting p53 or its upstream activator Chk2 are associated with resistance to DNA-
damaging chemotherapy in breast cancer. ATM (Ataxia Telangiectasia Mutated protein) is the key activator of p53
and Chk2 in response to genotoxic stress. Here, we sought to evaluate ATM’s potential role in resistance to
chemotherapy.
Methods: We sequenced ATM and assessed gene expression levels in pre-treatment biopsies from 71 locally
advanced breast cancers treated in the neoadjuvant setting with doxorubicin monotherapy or mitomycin
combined with 5-fluorouracil. Findings were confirmed in a separate patient cohort treated with epirubicin
monotherapy. Each tumor was previously analyzed for CHEK2 and TP53 mutation status.
Results: While ATM mutations were not associated with chemo-resistance, low ATM expression levels predicted
chemo-resistance among patients with tumors wild-type for TP53 and CHEK2 (P = 0.028). Analyzing the ATM-chk2-
p53 cascade, low ATM levels (defined as the lower 5 to 50% percentiles) or mutations inactivating TP53 or CHEK2
robustly predicted anthracycline resistance (P-values varying between 0.001 and 0.027 depending on the percentile
used to define “low” ATM levels). These results were confirmed in an independent cohort of 109 patients treated
with epirubicin monotherapy. In contrast, ATM-levels were not suppressed in resistant tumors harboring TP53 or
CHEK2 mutations (P > 0.5).
Conclusions: Our data indicate loss of function of the ATM-Chk2-p53 cascade to be strongly associated with
resistance to anthracycline/mitomycin-containing chemotherapy in breast cancer.
Introduction
Despite significant improvements in cancer therapy over
the last decades, resistance towards chemotherapy
remains the main obstacle to cure among patients suf-
fering from solid tumors [1].
The molecular mechanisms causing chemo-resistance
in breast cancer, as for most other cancer forms, are
poorly understood. While Topoisomerase-II amplified
tumors on average reveal enhanced anthracycline
sensitivity compared to non-amplified tumors [2-5], lack
of Topoisomerase-II expression may not explain anthra-
cycline resistance.
p53, the tumor suppressor protein encoded by the TP53
gene, plays a key role with respect to apoptosis but also
senescence, growth arrest and DNA repair [6,7]. Our
group has previously linked mutations in TP53, (in parti-
cular those affecting the L2/L3 DNA binding domains), to
resistance to anthracyclines and the related cytotoxic
compound, mitomycin, in primary breast cancers [8-10].
However, the observation that some tumors harboring
wild-type TP53 revealed resistance towards anthracycline
therapy made us hypothesize this could be due to
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inactivation of other genes acting up- or downstream in
the p53 functional pathway [11,12]. Excluding potential
correlations between genetic and epigenetic alterations
affecting cyclin-inhibitors and therapy resistance [8,13,14],
subsequently, we detected non-sense mutations in the
CHEK2 gene (coding for the Chk2 protein) in three
patients with primary breast cancers revealing anthracy-
cline resistance [8,15]. Chk2 phosphorylates p53 at Ser 20,
inhibiting MDM2-p53 protein binding [16] but also at sev-
eral sites located in the C-terminal domain of the p53 pro-
tein [17]. While Chk2 activates multiple downstream
targets in addition to p53, and the p53 protein may be
activated through multiple post-transcriptional events
[17], the finding that CHEK2 mutations may substitute for
TP53 mutations as a cause of chemo-resistance indicates
Chk2 phosphorylation of the p53 protein to play a pivotal
role executing cell death in response to anthracycline ther-
apy in breast cancer.
Chk2 activation, in response to chemotherapy-induced
double strand breaks, is mediated through the Ataxia
Telangiectasia Mutated (ATM) protein which phosphor-
ylates Chk2 at Thr 68 in response to DNA damage
caused by cytotoxic compounds or ionizing radiation
[18,19]. Further, ATM directly phosphorylates p53 at Ser
15, providing additional activation of p53 besides the Ser
20 phosphorylation [20,21].
Based on the evidence above, we hypothesized that loss
of ATM function could be a cause of anthracycline resis-
tance in breast cancers harboring wild-type TP53 and
CHEK2. While low expression of ATM has been found
associated with a poor prognosis among breast cancer
patients harboring wild-type TP53 tumors treated with
DNA-damaging chemotherapy [22], notably the direct
effect of ATM status on response to anthracycline ther-
apy (predictive value) has not been addressed previously.
In this study, we performed complete ATM gene
sequencing and determined ATM mRNA levels in breast
tumor samples selected based on TP53 and CHEK2
mutation status and clinical outcome. All samples were
from primary breast cancers treated with pre-surgical
("neoadjuvant”) therapy in controlled studies from which
TP53 and CHEK2 gene mutation status had been pre-
viously characterized and the direct response to che-
motherapy (doxorubicin, 5FU/mitomycin or epirubicin)
as well as long-term outcome for each individual patient
determined. We found low levels of tumor ATM expres-
sion to predict chemo-resistance in tumors wild-type for
TP53 and CHEK2 but not in tumors harboring TP53 or
CHEK2 mutations. Importantly, these findings were cor-
roborated by the findings that low ATM expression sig-
naled a poor prognosis among patients harboring TP53
and CHK2 wild-type tumors, contrasting an improved
prognosis in tumors harboring TP53/CHEK2 mutations.
These findings indicate the ATM-chk2-p53 cascade to be
an important pathway executing drug-induced cell death
in breast cancers in vivo.
Materials and methods
Patients
For this study we analyzed samples selected from three
prospective studies [8-10]. The selection of tumors for
this study was based on the patients’ response to therapy
and tumor TP53 and CHEK2 status, previously deter-
mined [8,10]. The rationale was to analyze an optimal
number of “poor” and “good” responders and tumors
mutated versus wild-type for TP53/CHEK2. Since the
majority of patients displayed partial response upon
treatment and wild-type status for TP53 and CHEK2,
only a subgroup of these were included for ATM analyses
and statistical comparisons. In contrast, we included all
tumors harboring TP53 /CHEK2 mutations and all
tumors resistant to therapy.
The numbers of patients included in the different ATM
analyses are listed in Table 1 with further details listed in
Additional file 1 Table S1. Cohort 1 (n = 71) included a
selection of 36 out of 91 patients enrolled in a prospective
study exploring the mechanisms of resistance to treatment
with doxorubicin in locally advanced breast cancer [10] as
well as all 35 patients from a similar prospective study
evaluating the mechanisms of resistance to 5-fluorouracil
and mitomycin (FUMI) [9]. In this cohort of 71 tumors,
material for DNA sequencing, mRNA expression analysis
and MLPA copy number analysis was available from n =
70, n = 69 and n = 66 tumors, respectively. For the first
part of the study, these patients were statistically evaluated
as an exploratory data set (Cohort 1).
For validation purposes and inclusion of a group of
patients treated with a non-anthracycline/mitomycin regi-
men, we analyzed samples from a study in which patients
with primary breast cancers were randomized to pre-surgi-
cal treatment with epirubicin (Cohort 2; n = 109; validation
cohort) versus paclitaxel (Cohort 3; n = 114; patients trea-
ted with a non-anthracycline-containing regimen) mono-
therapy [8,23]. Out of the 109 epirubicin treated patients, 2
were omitted from statistical analyses as protocol violators
(one sarcomatoid and one stage II tumor) and from the
114 paclitaxel treated patients, 8 were omitted from statisti-
cal analyses due to non-evaluable response to therapy, in
most cases due to early termination of treatment because
of paclitaxel toxicity (for details, see [8]). Here, ATM
expression was determined in the whole cohort, while
ATM gene sequencing was performed in subgroups of 41
(Cohort 2) and 38 (Cohort 3) individuals.
Before commencing chemotherapy, each patient parti-
cipating in one of these trials had an incisional tumor
biopsy as described previously [9]. All tissue samples
were snap-frozen immediately on removal in the surgi-
cal theater.
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Each of the studies was approved by the local Ethical
Committee, and all patients gave written informed
consent.
Nucleic acid isolation and cDNA synthesis
Genomic DNA was isolated from tumor biopsies using
QIAamp DNA Mini kit (Qiagen, Chatsworth, CA, USA)
according to the manufacturer’s protocol. Total RNA
was purified by Trizol (Life Technologies, Inc., Grand
Island, NY, USA) extraction from snap-frozen tissue
samples according to manufacturer’s instructions. After
extraction, the RNA was dissolved in DEPC treated
ddH2O. First-strand cDNA synthesis was carried out
using oligo-dT and Random Hexamer primers with the
Transcriptor Reverse Transcriptase system (Roche,
Basel, Switzerland) in accordance with the manufac-
turer’s instructions.
Mutation screening
Screening for mutation and small insertions/deletions
was performed by PCR-amplification and subsequent
sequencing of all the exons of the coding region of ATM
[GenBank: NT 033899] as well as the previously
described bidirectional promoter area [17]. All amplifica-
tions were performed using the Kod XL DNA polymerase
system (Novagen, Madison, WI, USA) according to the
manufacturer’s instructions. Primers and thermal condi-
tions for the primer annealing step are listed in Addi-
tional file 1 Table S2. Prior to sequencing, PCR products
were purified using the ExoSAP-IT kit (GE Healthcare,
Little Chalfont, UK) according to the manufacturer’s
instructions. Sequencing was done using BigDye version
1.1 cycle sequencing kit (ABI, Foster City, CA, USA) with
specific forward or reverse sequencing primers, according
to the manufacturer’s instructions. Thermal conditions
were 30 cycles of denaturation at 94°C for 10 seconds,
annealing at 50°C for 5 seconds and elongation at 60°C
for 4 minutes. Capillary electrophoresis, data collection
and sequence analysis were performed on an automated
DNA sequencer (ABI 3700). Resulting sequences from
patient samples were analysed using Genebank accession
u33841 as reference.
Quantitative PCR
Quantitative PCRs were performed using specific Hydroly-
sis Probes targeting ATM on a Light Cycler 480 instru-
ment (Roche). Reaction mixes were made according to the
instructions from the manufacturer of the kit Lightcycler
480 ProbesMaster (Roche). Relative mRNA expressions
were normalized to rpP2 gene expression in a two-colour
duplex reaction. Primers/probes for detection of ATM (5’-
GCAGATGACCAAGAATGCAA-3’, 5’- GGCCTGCTGTA
TGAGCAAAT-3’ and 6FAM-TGGAAGAAGGCACTGTG
CTCA-BBQ) and rpP2 (5’-gaccggctcaacaaggttat-3’, 5’-
ccccaccagcaggtacac-3’ and Cy5-agctgaatggaaaaaacattgaa-
gacgtc-BBQ), were designed to be used in the same condi-
tions of real-time PCR amplification. After initial
denaturation at 95°C for five minutes, samples were run
through 50 cycles of the following conditions: Denatura-
tion for 10 seconds at 95°C and elongation at 55°C for
25 seconds. All reaction data were converted into relative
concentrations through the use of an internal standard
curve in each run. Each analysis was performed in
triplicate.
Copy number analyses
ATM gene copy numbers were determined by MLPA
analysis using the SALSA MLPA P190 probemix (MRC-
Holland, Amsterdam, The Netherlands) according to the
manufacturer’s instructions. Peak areas of all MLPA
products resulting from ATM specific probes were nor-
malized and compared to references as previously
described [24].
Promoter methylation analyses
Genomic DNA from patients was modified by bisulfite
conversion, using the EZ DNA Methylation Gold Kit
(Zymo Research, Irvine, CA, USA). Primers were used to
specifically amplify methylated and unmethylated DNA
immediately upstream of the ATM transcription start
site (for primer sequences, see [25]). Methylation- and
non-methylation-specific PCRs (MSP and USP) were per-
formed using the AmpliTaq Gold DNA Polymerase sys-
tem (Applied Biosystems, Foster City, CA, USA) in a
50 μl solution containing 1X PCR buffer, 1.5 mM MgCl2,
Table 1 Patients included in ATM analyses
Cohort ATM coding region ATM promoter
No. Therapy Mutations mRNA levels Copy no. Mutations Methylation Survival
n n n n n n
1 Doxorubicin 70 69 69 70 - 69
FUMI
2 Epirubicin 41 1091 - 41 1091 1091
3 Paclitaxel 38 1142 - 38 - 1142
1 Among the 109 patients, two were omitted from statistical analyses as protocol violators.
2 Among the 114 patients, 8 had non-evaluable response to therapy.
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0.5 mM of each deoxynucleotide triphosphate, 0.2 μM of
each primer and approximately 50 ng of modified geno-
mic DNA. The thermocycling conditions for both the
MSP and the USP were an initial 5 minutes of denatura-
tion at 94°C followed by 35 cycles of 30 sec at 94°C,
30 sec at 57.6°C, and 30 sec at 72°C. Included in each run
were a methylated control (CpGenome Universal Methy-
lated DNA, Millipore, Billerica, MA, USA), an unmethy-
lated control (modified DNA from healthy donors) and a
negative control (water). After amplification, the PCR
products were separated and visualized on a 3% agarose
gel.
Immunohistochemistry
Sections of 5 μm were prepared from formalin-fixed, par-
affin-embedded tumors. Immunohistochemical staining
was performed using a rabbit anti-human ATM monoclo-
nal antibody (Abcam, Cambridge, UK). For the staining
procedure, the DAKO Envision HRP rabbit kit (DAKO,
Glastrup, Denmark) with DAB as detection method was
used. The scoring of stained section was performed using
four grades related to proportion of positive tumor cells: 0:
0%; 1: 1 to 10%; 2: 11 to 50%; 3: > 50%.
Statistical analyses
Comparisons of the ATM mRNA expression levels were
performed using the Mann-Whitney rank test (for inde-
pendent samples). Comparisons of observed mutations
between different groups of patients were performed using
Fischer exact test. All P-values given are two-sided, and
for Fischer exact test, cumulative. Multivariate analyses
were performed by binary logistic regression, defining
TP53- and CHEK2 mutations as categorical variables and
ATM mRNA levels as a continuous variable. Survival ana-
lyses were performed by Kaplan-Meier, and subsets of
patients were compared using the log-rank test. Deaths for
reasons other than breast cancer were treated as censored
observations. All statistical analyses were performed using
the SPSS 15.0/PASW 17.0 software package (SPSS Inc.
Chicago, IL, USA) and/or Simple Interactive Statistical
Analysis (SISA).
Results
ATM mutations in locally advanced breast cancer
ATM gene alterations recorded through sequencing (n =
149 tumors) and MLPA analysis (n = 69 tumors) in dif-
ferent breast cancer cohorts are summarized in Table 2
(see Materials and methods for cohort details). Most
alterations found were of germline origin and previously
observed by others [26-29] in multiple patients, indicat-
ing these changes to be polymorphic variants rather
than mutations contributing to a malignant phenotype.
Seven of the mutations observed have, to our knowl-
edge, not previously been reported (Table 2). Each of
these variants was observed in a single patient only. Per-
ipheral blood lymphocytes were available for four of
these patients. Out of these four, one mutation proved
to be somatic, whereas three were also found in lym-
phocyte DNA, indicating the mutations to be of germ-
line origin.
ATM mutations are not associated with chemo-resistance
We compared gene alterations in tumors progressing on
therapy (PD) versus tumors not progressing (stable dis-
ease or an objective response) classified according to the
UICC criteria [30] as previously described [10,31]. The
frequency of ATM mutations was similar among
patients with progressive disease (PD) upon treatment
and those responding to therapy in any of the cohorts
analyzed (data not shown). Stratifying tumors into wild-
type versus TP53/CHK2 mutated ones did not reveal
any imbalance regarding ATM mutation incidence
between these subgroups.
Assessing the possibility that some ATM variants in par-
ticular could be associated with therapy resistance, we
compared individual mutations observed among PD-
patients with those observed in responders. However,
none of the individual mutations (Ser49Cys, Asp1853Asn,
Phe858Leu or Pro1054Arg) was found at higher incidence
among patients progressing on therapy as compared to
responders.
We further assessed the potential impact of ATM muta-
tions on response to paclitaxel monotherapy. Contrasting
what has been recorded for the anthracyclines, TP53/
CHEK2 mutations do not predict therapy resistance
towards the taxanes [23]. Five out of the 11 analyzed
patients displaying progressive disease upon paclitaxel
monotherapy treatment harbored ATM mutations (com-
pared to 10 out of 27 responders). Thus, no association
between ATM mutations and resistance to paclitaxel ther-
apy was recorded.
Low ATM expression levels predict chemo-resistance to
doxorubicin and mitomycin but not to paclitaxel in
tumors wild-type for TP53 and CHEK2
ATM mRNA levels were determined by qPCR in 69 out
of the 71 doxorubicin or 5-fluorouracil/mitomycin trea-
ted patients (Cohort 1) from whom RNA were available
(for two patients, one with partial response and one
with stable disease upon treatment, sufficient amounts
of RNA was lacking; Table 1). Results from these ana-
lyses revealed large differences in ATM mRNA levels in
the cohort, with a 56.9-fold ratio between the highest
and the lowest value recorded (Figure 1A).
No association between ATM mRNA levels and
ATM mutation status was observed (P > 0.5; Mann-
Whitney rank test). Further, since previous studies
have indicated that concomitant ATM and p53
Knappskog et al. Breast Cancer Research 2012, 14:R47
http://breast-cancer-research.com/content/14/2/R47
Page 4 of 12
inactivation is underrepresented in breast tumors [22],
we assessed the ATM levels among TP53 mutated ver-
sus wild-type tumors; no difference between the two
groups was observed (P > 0.4).
Considering the 18 patients with progressive disease,
these patients displayed a non-significant trend towards
lower ATM mRNA levels as compared to the respon-
ders (P = 0.104; Mann-Whitney rank test), with 12 out
of 18 expressing ATM levels below the median value of
the cohort (P = 0.168; Fischer exact test).
To test the hypothesis that low ATM expression may
be an alternative mechanism inactivating the p53 path-
way, we compared ATM mRNA expression levels in
tumors resistant to chemotherapy despite harboring
wild-type TP53/CHEK2 (Group A Table 3; n = 5) to the
other tumors (Group B + C + D; n = 64) in the same
cohort (Cohort 1). ATM-levels were lower among
tumors in Group A as compared to the tumors in the
other three groups (P = 0.012). Stratifying the latter
tumors (n = 64) into TP53/CHEK2 mutated (Group B +
D; n = 40) and TP53/CHEK2 wild-type (Group C; n =
24) tumors, the tumors in the A group expressed lower
ATM levels when compared to each of these two sub-
groups (P = 0.010 and 0.028, respectively). Notably, each
of the tumors in Group A revealed an ATM expression
level in the lower tertile of the total cohort.
In contrast, no difference in ATM-levels between PD-
tumors harboring TP53 or CHEK2 mutations (Group B)
and the other tumors in this cohort was found (P > 0.5);
neither did we record any difference in ATM levels
between mutated tumors progressing on chemotherapy
and mutated tumors responding to treatment (Group B
vs. Group D; P > 0.5)
In the epirubicin treated validation cohort (n = 107,
Cohort 2, Table 1), 6 out of 10 patients with progressive
disease on therapy previously were found mutated in the
TP53 or CHEK2 genes (Group B) [8], limiting the number
of patients with a PD despite harboring wild-type TP53
and CHEK2 (Group A) to 4. Still, these four patients each
revealed low ATM expression levels as compared to the
rest of the tumors (n = 103; P = 0.092; Figure 1B), as well
as when compared to the subgroups of other wild-type
TP53/CHEK2 tumors (n = 79; P = 0.097) or tumors har-
boring TP53/CHEK2 mutations (n = 25; P = 0.094).
To evaluate whether the effect of low ATM status was
specific to DNA-damaging chemotherapy, we analyzed
the predictive impact of ATM expression levels on
response to paclitaxel monotherapy (Cohort 3, Table 1).
Here, we observed no difference in ATM expression
levels between patients revealing primary resistance to
paclitaxel with (n = 5) or without (n = 7) concomitant
TP53/CHEK2 mutations and patients obtaining an
Table 2 ATM mutations
Mutation Exon A. A change Cohort 1
Dox Fumi
n (%)
Cohort 2
Epi
n (%)
Cohort 3
Pac
n (%)
Germ line Previous
obs.1
C146G 4 Ser 49 Cys 3 (4.3) 0 (0.0) 1 (2.6) ND Yes2,3,4
C735T 8 - 2 (2.9) 4 (9.8) 1 (2.6) Yes Yes2,3,4
A737C 8 Asn 246 Thr 0 (0.0) 1 (2.4) 0 (0.0) ND No5
C1009T 9 Arg 337 Cys 1 (1.4) 0 (0.0) 0 (0.0) No No5
A1792G 12 Ile 598 Val 1 (1.4) 0 (0.0) 0 (0.0) Yes No5
T2572C 18 Phe 858 Leu 2 (2.9) 4 (9.8) 0 (0.0) Yes Yes2,3,4
C3161G 23 Pro 1054 Arg 5 (7.1) 5 (12.2) 1 (2.6) Yes Yes2,3,4
A3341G 24 Lys 1114 Arg 0 (0.0) 0 (0.0) 1 (2.6) Yes No5
C4258T 30 Leu 1420 Phe 3 (4.3) 2 (4.9) 0 (0.0) Yes Yes2,3,4
T4324C 30 Tyr 1442 His 1 (1.4) 0 (0.0) 0 (0.0) Yes No5
C4578T 31 - 8 (11.4) 5 (12.2) 9 (23.7) Yes Yes2,3,4
A5071C 35 Ser 1691 Arg 1 (1.4) 0 (0.0) 0 (0.0) ND Yes2,3,4
G5557A 38 Asp 1853 Asn 13 (18.6) 9 (22.0) 11 (28.9) Yes Yes2,3,4
T5793C 40 - 1 (1.4) 1 (2.4) 0 (0.0) ND Yes2,3,4
C6217G 44 Leu 2073 Val 0 (0.0) 1 (2.4) 0 (0.0) ND No5
T7390C 51 Cys 2464 Arg 0 (0.0) 0 (0.0) 1 (2.6) Yes Yes2,3,4
del A 8432 59 Frameshift 0 (0.0) 0 (0.0) 1 (2.6) ND No5
Overview of the ATM mutations observed in the cohorts of Doxorubicin/Fumi (n = 70), Epirubicin (n = 41) or Paclitaxel (n = 38) treated breast cancer patients.
1 Data from Dörk et al., Thorstenson et al., Bretsky et al. and the Leiden Open Variation Database [29]
1 Previously observed in Breast cancer
3 Common variant (considered non-pathogenic)
4 Pathogenic role unclear
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objective response/stable disease (n = 102; P > 0.2 for
both comparisons).
Low ATM expression levels may substitute for TP53/
CHEK2 mutations as a cause of chemo-resistance
Postulating low ATM expression and mutations affecting
TP53 and CHEK2 to be alternative mechanisms inactivat-
ing the p53 pathway (Figure 2A), we compared the fre-
quency of tumors having a “hit” in this pathway (either a
TP53 (L2/L3) or CHEK2 mutation or low ATM expres-
sion) among chemo-resistant versus tumors responding
to anthracycline/mitomycin chemotherapy. Defining low
ATM as the levels expressed by the lower 20% percentile
of the patients in the cohort, a “hit” in this pathway
(either low ATM expression level or a CHEK2/TP53
mutation) correlated to therapy resistance (P = 0.0267;
Table 4). Further, we evaluated the robustness of the
model by performing repeated analysis using ATM cut-
off values ranging between the 5% and 50% percentile of
the cohort defining tumors with “low expression” for
ATM (Figure 2B). Notably, the different models all
revealed a statistically significant correlation between
defects in the p53 pathway (defined as L2/L3-TP53/
CHEK2 mutations or low level ATM expression) and
therapy resistance defined as PD on treatment (P-values
varying from 0.001 to 0.027; Figure 2B). In a multivariate
analysis (logistic regression), L2/L3-TP53/CHEK2 muta-
tions or low level ATM expression was also confirmed to
be significantly associated with resistance to therapy
(overall test of the model, P = 0.010).
A 
B 
Patients with PR or SD 
Patients with PD harboring mutated TP53 / CHK2 
Patients with PD harboring wild-type TP53 / CHK2 
Figure 1 Relative intratumor ATM mRNA levels among patients with locally advanced breast cancer. (A) ATM mRNA levels among patients
receiving neoadjuvant doxorubicin or 5-fluorouracil/mitomycin (n = 69; Cohort 1). Blue bars represent patients displaying stable disease or response to
treatment. White bars represent patients with progressive disease (PD) and TP53 or CHEK mutations, while red bars (with arrows) indicate PD-patients
with wild-type TP53 and CHEK2. (B) ATM mRNA levels among patients receiving neoadjuvant epirubicin (n = 109; Cohort 2). Color key as for A.
Table 3 Grouping of tumors used for evaluation of ATM’s
impact on resistance to chemotherapy
TP53/CHEK2 status
Wild-type Mutated
Progressive disease A B
Responders C D
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To confirm this observation, similar analyses were per-
formed on a validation cohort of patients having epirubi-
cin monotherapy (Cohort 2, Table 1). We confirmed the
observation that low ATM expression levels or mutations
affecting either TP53 (L2/L3) or CHEK2 to be associated
with anthracycline resistance (P = 0.0074; Table 5). Using
different cut-off values classifying between 5% and 50%
of the tumors as “low ATM expressors”, we confirmed
the model to be robust in this cohort as well (P-values
varying from 0.20 to < 0.01; notably, setting a cut-off
between 5% and 25%, all P-values were < 0.05; Figure 2B;
multivariate analysis: overall test of the model; P = 0.007).
ATM immunostaining
To evaluate whether the differences in ATM mRNA levels
were reflected at the protein level, we performed immuno-
histochemical staining on samples from the initial cohort
(Cohort 1, Table 1). While most samples revealing high
mRNA levels displayed strong ATM protein staining, inter-
estingly, some samples stained strongly despite expressing
low mRNA levels; thus, there was a lack of statistical corre-
lation between ATM mRNA and IHC-staining levels (P >
0.5). However, in the group of tumors with progressive
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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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 TP53 and CHK2 wt  
PD-patients with  
low ATM levels
TP53 and CHK2 wt
PD patients with 
low ATM levels
*  patient with both  
TP53 and CHK2 mutation 
A B
Figure 2 Alterations in the p53 functional pathway predicts chemoresistance. (A) Schematic illustration of the three central players (ATM,
Chk2 and p53), activated in response to chemotherapy induced double stranded DNA breaks. All patients in this study with tumors displaying
lack of response to neoadjuvant treatment with doxorubicin or 5-fluorouracil/mitomycin (left) or epirubicin (right) harbor alterations affecting at
least one of these factors, leaving the functional pathway disrupted and thus, cells resistant to therapy. (B) Graphs displaying P-values for the
correlations between defects in the p53 functional pathway, defined as low expression of ATM or mutations affecting either TP53-L2/L3 domains
or CHEK2, and lack of response to neoadjuvant treatment with doxorubicin or 5-fluorouracil/mitomycin (blue line) or epirubicin (red line).
Percentage on the X-axis indicates the portion of the patients cohorts defined as “low ATM expressors”.
Table 4 Correlation between alterations in TP53/CHEK2/
ATM ("hit”) and in vivo resistance to doxorubicin/FUMI
Hit Non-Hit
Progressive disease 141 42
Responders 233 284
P = 0.0267
Cohort 1 (Dox/Fumi)
1 Patients lacking response to therapy/with mutations in TP53 (L2/L3) or
CHEK2 or low expression of ATM (lower 20% percentile of cohort)
2 Patients lacking response to therapy/without mutations in TP53 (L2/L3) or
CHEK2 low expression of ATM (lower 20% percentile of cohort)
3 Patients with response to therapy (SD, PR or CR)/with mutations in TP53 (L2/
L3) or CHEK2 or low expression of ATM (lower 20% percentile of cohort)
4 Patients with response to therapy (SD, PR or CR)/without mutations in TP53
(L2/L3) or CHEK2 or low expression of ATM (lower 20% percentile of cohort)
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disease and wild-type TP53 and CHEK2, one tumor only
was found to stain strongly for ATM.
ATM gene copy number
Out of the 70 patients from Cohort 1 sequenced for
point mutations, material for MLPA-analyses was avail-
able from 66 (all included among the 69 analyzed for
ATM expression levels). While no larger intragenetic
deletions or duplications were observed, 9 out of the 66
tumors harbored a reduced copy number for the entire
ATM locus. No association between ATM reduced copy
number and either ATM mRNA levels or response to
therapy was observed (P > 0.2 and P > 0.4, respectively).
ATM promoter mutations and hypermethylations
The observed difference in ATM mRNA levels could be
due to different mechanisms of promoter inactivation,
including mutations or hypermethylations.
Screening for potential ATM promoter hypermethyla-
tion in the patients treated with epirubicin (Cohort 2; n =
109), none displayed methylation of the ATM promoter.
Next, we sequenced the promoter region from position
-661 to +105 relative to the transcriptional start site
(sequence NT_033899; [32]) in 70 tumors from Cohort 1,
no mutations were recorded. The promoter area was found
to exist as two distinct haplotypes differing in positions
-635 (rs228589) and -10 (rs189037) relative to the tran-
scriptional start site. Homozygosity for the NT_033899
haplotype -635A/-10G was observed in 15 patients (21.4%),
22 patients (31.4%) were homozygous for the -635T/-10A
haplotype while 33 patients (47.1%) were heterozygotes.
No difference in ATM expression levels between patients
harboring the different genotypes were observed (P > 0.2;
Kruskal-Wallis rank test). This finding was confirmed in
Cohort 2 (data not shown).
Impact of c-myc amplifications
Our data indicate that events other than promoter
alterations, like deregulation of trans-acting factors, may
be responsible for the alterations in ATM expression
levels. N-myc induces expression of miR-421, which in
turn suppresses ATM levels [33]. However, while we
found the C-myc gene to be amplified in 12 out 69 dox-
orubicin/FUMI-treated tumors, no correlation between
C-myc amplification status and ATM expression levels
were recorded (P > 0.4; Mann-Whitney test).
ATM mRNA levels are not associated with breast cancer
subclasses
An interesting question is whether low ATM expression
may correlate to other tumor characteristics. Among
doxorubicin/mitomycin treated tumors analyzed here,
64 have previously been classified according to gene
expression profiling [34,35], defining 25 and 11 tumors
belonging to the Luminal A and B class, respectively, 12
belonging to the ERBB2+ class, 11 basal-like, while 5
were found belonging to the normal cell-like class. No
difference in ATM expression levels between tumors
belonging to the different subclasses were recorded
(data not shown).
ATM mRNA levels predict overall survival in breast cancer
patients
Recently, Jiang and colleges suggested low ATM levels on
a TP53 wild-type background to be associated with poor
survival while low ATM predicted improved survival in
patients harboring TP53 mutations [22]. While we
detected a non-significant trend in Cohort 1 (including 69
patients only), we confirmed low ATM levels to predict a
poor outcome in patients with tumors wild-type for TP53
and CHEK2 but to improve long-term outcome among
patients with tumors harboring TP53 or CHEK2 muta-
tions (Figure 3A, C). Further, we observed a significant dif-
ferential effect of ATM levels on survival pending on
TP53/CHEK2 mutation status in our larger confirmatory
set (Cohort 2; Figure 3B, D; P = 0.007; interaction between
TP53 status and ATM levels on survival P = 0.011).
In order to investigate whether these effects on long-
term overall survival were of general prognostic nature or
related to DNA damaging chemotherapy, we performed a
similar analysis on patients enrolled in the paclitaxel treat-
ment arm (Cohort 3). Here, we observed no effect of low
ATM levels on prognoses either among patients with
tumors wild-type or mutated for TP53/CHEK2 (data not
shown). This suggests the effect of ATM level on long-
term outcome may be related to treatment with DNA-
damaging agents.
Discussion
The mechanisms of resistance to chemotherapy in
breast cancer remains poorly understood. While large
studies have revealed a somewhat better response
related to high Ki67 expression [36] and gene expression
Table 5 Correlation between alterations in TP53/CHEK2/
ATM ("hit”) and in vivo resistance to epirubicin
Hit Non-Hit
Progressive disease 71 32
Responders 253 724
P = 0.0074
Cohort 2 (Epirubicin)
1 Patients lacking response to therapy/with mutations in TP53 (L2/L3) or
CHEK2 or low expression of ATM (lower 20% percentile of cohort)
2 Patients lacking response to therapy/without mutations in TP53 (L2/L3) or
CHEK2 low expression of ATM (lower 20% percentile of cohort)
3 Patients with response to therapy (SD, PR or CR)/with mutations in TP53 (L2/
L3) or CHEK2 or low expression of ATM (lower 20% percentile of cohort)
4 Patients with response to therapy (SD, PR or CR)/without mutations in TP53
(L2/L3) or CHEK2 or low expression of ATM (lower 20% percentile of cohort)
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profiles, such as a high Oncotype-DX score [37,38],
these represent non-specific correlations related to dif-
ferent treatment regimens. While topoisomerase-II
amplifications have been associated with improved sen-
sitivity to DNA damaging agents [39], lack of topoi-
somerase-II expression may not explain anthracycline
resistance in general.
We have previously shown mutations in TP53, in parti-
cular those affecting the DNA binding L2- or L3
domains, to predict resistance to chemotherapy in locally
advanced breast cancer [9,10]. Further, exploring the p53
functional pathway, we found mutations in CHEK2, the
gene coding for the p53 upstream activator Chk2, may
substitute for TP53 mutations, causing drug resistance in
tumors harboring wild-type TP53 [8]. Thus, the fact that
some tumors harboring wild-type TP53 and CHEK2
revealed anthracycline resistance made us postulate that
these tumors may have defects in other genes involved in
the same pathway. While p53 activation in response to
DNA damage involves ATM and Chk2 [19,21,26,27],
downstream activation of genes leading toward apoptosis
or senescence involves multiple, possible redundant,
pathways, including transcriptional dependent- as well as
independent pathways [40-44]. Thus, we hypothesized
inactivation of ATM, but not genes acting downstream
of p53, to be a mechanism hampering p53-induced cell
death in some tumors.
Contrasting our expectations, mutations in the ATM
gene did not correlate to chemo-resistance. Notably, most
of the mutations detected are common variants [26-28].
Among novel mutations observed in this study, we con-
firmed the mutation to be of germline origin in three out
of four patients from whom WBC DNA was available.
Thus, the mutations observed most likely have little
impact on the malignant phenotype of the tumors in
which they reside.
In contrast, we observed reduced ATM expression
levels in tumors revealing chemo-resistance despite har-
boring wild-type TP53/CHEK2, indicating ATM low
expression levels may substitute for TP53/CHEK2
Cohort 1 (Dox / FUMI) 
mut / high ATM
mut / low ATM 
Cohort 2 (Epi) 
wt / low ATM 
wt / high ATM 
TP
53
 
TP
53
 (L
2/
L3
) +
 C
H
K
2 
A 
C 
B 
D 
Figure 3 Impact of ATM expression levels on long-term survival. (A) Kaplan-Meier curves showing long-term survival among breast cancer
patients treated with doxorubicin or a combination of 5-fluorouracil and mitomycin in the neoadjuvant setting (Cohort 1), stratified by ATM
expression levels (above/below median) and TP53 mutation status. (B) Data corresponding to (A), but in a cohort of epirubicin treated patients
(Cohort 2). (C, D) Data corresponding to (A) and (B), but where mutated status is defined as TP53 mutation affecting the L2/L3 domains or
CHEK2 mutation.
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mutations in this respect. Importantly, this result was
corroborated by the finding that low ATM expression
was associated with a poor long-term outcome for
patients with tumors harboring wild-type TP53/CHEK2
but not among patients harboring TP53/CHEK2 muta-
tions across the different cohorts. The hypothesis that
this finding was due to the effect of DNA-damaging
chemotherapy was substantiated by the finding of no
effect of ATM expression levels on outcome among
patients treated with paclitaxel monotherapy. In con-
trast, low ATM levels were associated with improved
long-term survival in patients treated with anthracy-
clines/mitomycin harboring TP53/CHEK2 mutations.
This observation is in line with the findings of Jiang et
al. [22]. These authors found reduced ATM expression
to improve outcome in patients with tumors revealing
strong staining for p53 (a surrogate for TP53 mutations)
but a poor prognosis for patients with weak p53 staining
(a surrogate marker for wild-type gene status). Because
their patients received adjuvant and not primary che-
motherapy, direct assessment of chemo-sensitivity could
not be applied in their model.
If confirmed in subsequent studies, the findings in the
present work have important clinical implications. Given
the strong correlation between defects in the ATM-Chk2-
p53 pathway and resistance to DNA-damaging therapy, a
screen for functional status in this pathway may be a valu-
able pre-treatment test, indicating whether or not a given
patient is likely to respond to such therapy. Patients with
an inactive ATM-Chk2-p53 pathway may be spared an
unnecessary DNA-damaging treatment and instead given
alternative therapy, for example, microtubule poisons.
Conclusions
Taken together, our data point to p53 and its upstream
activators, Chk2 and ATM, as a functional pathway
executing response to DNA-damaging chemotherapy in
breast cancer patients. If this cascade is disturbed, by
TP53 or CHEK2 mutations or low ATM expression
levels, response to therapy may be blunted. Thus,
patients harboring tumors with these defects should
receive alternative treatment.
Additional material
Additional file 1: Cohorts and primers. Additional file 1 contains Table
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